Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: * Participant is eligible to be included in the study only if all the following criteria are met: 1. The participant (or legally acceptable representative if applicable) provides written consent for the trial. 2. Participant is at least 21 years of age on the day of signing informed consent 3. Has a locally or centrally determined histologically or cytologically confirmed diagnosis of Epstein Barr Virus (EBV)-positive nasopharyngeal carcinoma Note: The EBV status is to be determined by the EBV-encoded small RNA in situ hybridization (EBER in situ hybridization \[ISH\]) assay. If EBV-positive status has been previously determined by EBER ISH assay, then no re-testing is required. If EBV status by EBER ISH assay has not been previously determined, tumour tissue from archival tissue may be submitted for EBV determination. 4. Has recurrent or metastatic (R/M) disease not amenable to curative local therapy (surgery or radiation) 5. Must have seen at least 1 p…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source